Chris Beddard[email protected]InfectiousThe next phase of diagnostic testing is here and ready to scaleIt is time to provide more advanced insight on patient health and more informed treatment options for clinicians in the U.S. Few diagnostic tools and systems on the market today are available to scale and even fewer provide extended genotyping capabilities. This gap can hamper patient care by masking or misdiagnosing illnesses and strains, potentially leading physicians to advise treatment plans that lack precision or that may be unnecessary.November 10, 2021Page 1 of 1Top StoriesMergers & Acquisitions$16.5B CDMO deal unhindered by role in broader pharma supply chainNovo Holdings greenlighted by European Commission to take control of U.S.-based CDMO.Compliance and RegulationTexas lab owner accused of $79M RPP fraud schemeFDA Warning LetterFDA sounds bacteria alarms over CGMP violations in MaineResearch and DevelopmentRevvity broadens work in newborn testing for NHS EnglandSponsor ContentBody composition in patients treated with Ozempic